Feasibility of immersive 40 Hz gamma sensory stimulation in early-stage Alzheimer's disease.
A single immersive 40 Hz session was tolerated by all 11 participants and produced a stronger EEG response at the stimulation frequency than baseline or sham. Exploratory memory-task findings were encouraging, but the study did not test repeated use or sustained everyday benefit.
Reis C, Hainke L, Headley G, Navarro S, Zanto TP, Certain R.
The journal of prevention of Alzheimer's disease · Publication date: 2026-09-25
Added to site: 2026-09-28
DOI: 10.1016/j.tjpad.2026.100679
Electronic publication date verified in Europe PMC. This source date is separate from the site's addition date.
- Modalities
- EEG, Gamma sensory stimulation, Virtual reality
- Clinical focus
- Alzheimer's disease, Feasibility, Target engagement
- Population
- People with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
- Sample
- 11 participants; all completed the session
- Intervention / method
- Immersive audiovisual virtual-reality environments modulated at 40 Hz while EEG was recorded; two of three environments also included a sham condition
- Comparator
- Baseline and within-subject sham stimulation
Clinician summary
No serious adverse event or discontinuation was reported. Frequency-specific EEG response exceeded baseline and sham at p < 0.001. Exploratory recall and recognition of encoded video-word pairs favored 40 Hz over sham after false-discovery-rate adjustment, all adjusted p < 0.05.
How to interpret the findings
The sample was very small, exposure was limited to one session, and the behavioral outcomes were exploratory task measures rather than validated longitudinal cognitive or functional endpoints. Two environments included sham, the abstract does not report blinding success or effect sizes, and extensive inventor, employment, equity and advisory relationships require independent replication.
Equipment and disclosures
Immersive virtual-reality audiovisual stimulation with concurrent EEG; the checked abstract does not provide product specifications or a complete stimulation parameter set.
The PubMed record reports patents pending to Clarity Health Technologies, a corresponding author who is co-founder and chief scientific officer, and several coauthors who are employees, advisers, equity holders or inventors associated with the technology.
Related evidence
Compare findings from the same clinical area, including mixed results.
- Safety and feasibility of accelerated deep transcranial magnetic stimulation for stimulant use disorder: A pilot study · Mixed
- Clinical efficacy of non-pharmacological interventions on cognitive improvement in patients with mild to moderate Alzheimer's disease: A systematic review and Bayesian network meta-analysis. · Positive with limitations
- Feasibility and Acceptability of Perioperative Application of Biofeedback-Based Virtual Reality vs Control for Pain and Anxiety in Children and Adolescents Undergoing Surgery: Pilot Randomized Controlled Trial. · Positive with limitations
- Bilateral Angular Gyrus 810-nm Transcranial Near-Infrared Stimulation Reshapes Brain Network: Ameliorate Alzheimer's Disease Cognitive Deficits. · Positive with limitations
- Temporal-Targeted Accelerated 40 Hz tACS Enhances Cognitive Function and Network Integration in Alzheimer's Disease: A Randomized Clinical Trial. · Positive with limitations
- Real-time fMRI feedback guides self-generated cognition toward upregulation of hippocampal activity. · Positive with limitations
Summary prepared with AI assistance. Source verification does not imply an independent replication or a clinician's endorsement. Read our review method.